Lantheus Welcomes Julie Eastland to Its Board
Lantheus Holdings, Inc. (NASDAQ: LNTH) is excited to announce that Julie Eastland has joined its Board of Directors. This significant appointment, effective September 3, 2024, underscores Lantheus’ dedication to strengthening its leadership team with individuals who possess invaluable expertise. With this addition, the Board now consists of ten directors, eight of whom are independent, enhancing its governance structure.
Driving Success Through Expertise
Mary Anne Heino, Chairperson of the Board at Lantheus, shared her enthusiasm regarding Ms. Eastland's appointment: “We are thrilled to welcome Julie Eastland to the Lantheus Board. Her extensive knowledge in finance, strategic planning, operations, and transactions will be vital for our growth and innovation.” Heino highlighted that Ms. Eastland’s impressive track record aligns perfectly with their vision for the future of radiopharmaceuticals.
New Director's Perspective
Julie Eastland expressed her eagerness to join the team, stating, “I am excited to collaborate with such a talented and experienced group to support the company’s upcoming initiatives. With a strong emphasis on innovation and excellence, I’m confident we will achieve significant advancements in enhancing patient care through advanced solutions.”
Julie Eastland's Remarkable Experience
Ms. Eastland brings a wealth of experience to the table, having served as an independent director and chair of the audit committee for Dynavax Technologies Corporation (NASDAQ: DVAX), as well as an independent director for Veana Therapeutics, a private company. Previously, she was the Chief Executive Officer at Harpoon Therapeutics until its acquisition by Merck in 2024, demonstrating her strong leadership skills. Her career also includes roles as Chief Operating Officer and Chief Financial Officer at ReCode Therapeutics, along with executive positions at Rainier Therapeutics and Cascadian Therapeutics.
Academic Credentials
Julie holds an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University, showcasing the solid academic foundation that supports her successful career in the biotech and finance sectors.
A Leader in Radiopharmaceuticals
Lantheus is recognized as a pioneering company in the radiopharmaceutical industry, dedicated to providing exceptional solutions that enable clinicians to Find, Fight, and Follow diseases, ultimately improving patient outcomes. With over 65 years of experience, Lantheus continues to push the boundaries of innovation, paving the way for new advancements in healthcare.
Contact Information for Inquiries
If you have any questions, please contact:
Lantheus Contact:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com
Frequently Asked Questions
Who is the new board member at Lantheus?
The new board member is Julie Eastland, an experienced executive in biotechnology and finance.
What will Julie Eastland's role be at Lantheus?
She will serve on the Board's Audit Committee.
How has Lantheus demonstrated its commitment to innovation?
Lantheus focuses on delivering transformative radiopharmaceutical solutions and has been a leader in the field for over 65 years.
What is Lantheus known for?
Lantheus specializes in radiopharmaceuticals, aiming to enhance patient outcomes by offering advanced solutions for clinicians.
How can someone contact Lantheus for inquiries?
For inquiries, you can reach Mark Kinarney at 978-671-8842 or email ir@lantheus.com.
